mProX™ Human PAK1 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Activation of PAK1 promotes post-ischemic stroke functional recovery in aged mice. Rac1, a protein involved in axonal regeneration and angiogenesis, declined in the brain as mice aged. Overexpression of Rac1 improved cognitive and sensorimotor recovery after stroke, while inhibition of Rac1 worsened outcomes. PAK1 is associated with skeletal muscle development in ducks. Comparative transcriptomic analysis of different duck breeds revealed that PAK1, along with other genes, is involved in skeletal muscle growth and myogenesis. PAK1 is implicated in therapy resistance in melanoma. PAK1 has been found to decrease cell sensitivity to programmed cell death, enhance growth-promoting molecular pathways, and contribute to an immunosuppressive tumor microenvironment. Inhibition of PAK1 may enhance the efficacy of anti-melanoma treatments. PAK1 mutation within the regulatory CRIPaK domain is associated with severe neurodevelopmental disorders in children. Novel de novo variants in PAK1 were identified in patients with macrocephaly, neurodevelopmental impairment, and drug-resistant epilepsy. The mutations were found to affect the autoinhibition of PAK1 and highlight a potential disease mechanism. PAK1-mediated cytoskeleton rearrangement promotes SARS-CoV-2 entry and ACE2 autophagic degradation. ACE2, the receptor for SARS-CoV-2, is endocytosed, degraded via autophagy, and restored on the cell surface through PAK1-mediated cytoskeleton rearrangement. Inhibition of PAK1 suppresses SARS-CoV-2 infection and reduces lung viral load and pulmonary inflammation in animal models.